Welcome to our dedicated page for Cocrystal Pharma SEC filings (Ticker: COCP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides organized access to Cocrystal Pharma, Inc. (Nasdaq: COCP) SEC filings, allowing readers to review the company’s official regulatory disclosures alongside AI-generated highlights. Cocrystal is a clinical-stage biotechnology company developing structure-based antiviral therapeutics targeting influenza viruses, coronaviruses, noroviruses and hepatitis C viruses, and its filings describe how these programs are financed and advanced.
Here you can review current reports on Form 8-K, which Cocrystal uses to disclose material events. Recent 8-K filings have reported quarterly financial results, FDA Investigational New Drug (IND) clearance and a Study May Proceed Letter for a Phase 1b human challenge study with CDI-988, an oral broad-spectrum 3CL protease inhibitor for norovirus, as well as an NIH Small Business Innovation Research (SBIR) Phase I award supporting an influenza A/B polymerase complex program. Other 8-Ks detail registered direct offerings and private placements of common stock and warrants, including insider participation and the terms of securities purchase agreements.
The page also links to registration statements such as the Form S-1 filed in 2025, which registers the resale of shares issuable upon exercise of outstanding warrants originally issued in a private placement concurrent with a registered direct offering. These documents outline the company’s capital structure, risk factors and use of proceeds related to COCP shares and associated warrants.
Stock Titan’s tools surface AI-powered summaries of lengthy filings, helping users quickly understand key points from 8-Ks, S-1 registration statements and other reports without reading every page. Investors can also track disclosures related to equity financings, warrant terms and listing information for COCP on The Nasdaq Capital Market. This filings hub is intended as a starting point for deeper review of Cocrystal’s official SEC documents on EDGAR.
Cocrystal Pharma director-affiliated trust buys additional shares. An entity associated with director and 10% owner Phillip Frost reported purchasing 50,000 shares of Cocrystal Pharma common stock on 02/06/2026 at a weighted average price of $0.9456 per share, with trades ranging from $0.8899 to $0.9880.
After this transaction, Frost Gamma Investments Trust is reported as indirectly holding 1,888,551 shares. Separately, 27,100 shares are held directly, including common stock issuable upon vesting of restricted stock units. Dr. Frost disclaims beneficial ownership of the trust-held and certain other shares except to the extent of any pecuniary interest.
Cocrystal Pharma is granting new non-qualified stock options to its directors, executive officers and a consultant under its 2025 Equity Incentive Plan. The options have a 10-year term, an exercise price equal to the closing price on January 8, 2026, and become effective upon execution of the company’s standard option agreement.
Half of each grant vests on January 9, 2027, with the remaining half vesting in eight equal quarterly installments starting March 31, 2027, contingent on continued service. Directors such as Dr. Roger Kornberg and Dr. Philip Frost each received 24,615 options, while James Martin and Sam Lee each received 49,229 options, and a consultant received 40,000 options. The Compensation Committee also approved a $50,000 cash award to Dr. Kornberg for his role as chairman of the Scientific Advisory Board.
Cocrystal Pharma director Roger Kornberg reported a grant of non-qualified stock options on a Form 4. On January 9, 2026 he received stock options to acquire 24,615 shares of common stock at a $1.10 exercise price, expiring on January 9, 2036. The options were granted under Cocrystal Pharma’s 2025 Equity Incentive Plan and approved by the board’s Compensation Committee under Rule 16b-3.
According to the vesting terms, one-half of the options will vest and become exercisable on January 9, 2027. The remaining half will vest and become exercisable in eight equal quarterly installments starting March 31, 2027, as long as Kornberg continues to serve as a director on each vesting date.
Cocrystal Pharma director Richard C. Pfenniger Jr. reported receiving a grant of non-qualified stock options on January 9, 2026. The award covers 16,410 stock options with an exercise price of $1.10 per share, giving him the right to buy Cocrystal Pharma common stock at that price in the future. The options were granted under the company’s 2025 Equity Incentive Plan.
These options vest over time, meaning he earns the right to exercise them gradually. One-half of the grant will vest and become exercisable on January 9, 2027. The remaining half will vest in eight equal quarterly installments starting on March 31, 2027, as long as he continues to serve as a director on each vesting date.
Cocrystal Pharma, Inc. reported that President and Co-CEO Sam Lee received a grant of 49,229 non-qualified stock options on January 9, 2026 under the company’s 2025 Equity Incentive Plan. The options give the right to buy common stock at an exercise price of $1.1 per share and were acquired at no cost.
According to the vesting schedule, one-half of the options will vest and become exercisable on January 9, 2027. The remaining half will vest in eight equal quarterly installments starting March 31, 2027, as long as Lee continues to serve as an officer on each vesting date. All 49,229 derivative securities are reported as directly owned following this grant.
Cocrystal Pharma, Inc. reported that director Fred Hassan received a grant of 16,410 non-qualified stock options on January 9, 2026. The options have an exercise price of $1.10 per share, were granted under the company’s 2025 Equity Incentive Plan, and were approved by the Compensation Committee under Rule 16b-3. One-half of the grant vests and becomes exercisable on January 9, 2027, with the remaining half vesting in eight equal quarterly installments starting on March 31, 2027, as long as Hassan continues to serve as a director on each vesting date.
Cocrystal Pharma Co-CEO and CFO Martin James Joseph received a grant of 49,229 non-qualified stock options on January 9, 2026. These stock options give him the right to buy up to 49,229 shares of Cocrystal Pharma common stock at an exercise price of
Half of the options will vest and become exercisable on January 9, 2027. The remaining half will vest in eight equal quarterly installments starting March 31, 2027, as long as he continues to serve as an officer of the company on each vesting date. The grant was approved by the board’s Compensation Committee under the company’s 2025 Equity Incentive Plan and was reported as a direct beneficial holding.
Cocrystal Pharma, Inc. reported that director and 10% owner Phillip Frost received a grant of stock options. On
Half of the options vest and become exercisable on
Cocrystal Pharma director Anthony J. Japour reported a new equity award. On January 9, 2026, he received non-qualified stock options to purchase 16,410 shares of Cocrystal Pharma common stock at an exercise price of
The options vest over time: one-half becomes exercisable on January 9, 2027, and the remaining half vests in eight equal quarterly installments beginning March 31, 2027, as long as he continues to serve as a director on each vesting date.
Cocrystal Pharma director Steven D. Rubin reported receiving non-qualified stock options for 16,410 shares of Cocrystal Pharma common stock on January 9, 2026. The options have an exercise price of $1.10 per share and were granted under the company’s 2025 Equity Incentive Plan, approved by the Compensation Committee of the Board.
Half of these options vest and become exercisable on January 9, 2027. The remaining half vests in eight equal quarterly installments starting March 31, 2027, as long as Rubin continues to serve as a director on each vesting date. After this grant, he beneficially owns stock options for 16,410 shares, held directly.
FAQ
What is the current stock price of Cocrystal Pharma (COCP)?
What is the market cap of Cocrystal Pharma (COCP)?
